https://www.selleckchem.com/pr....oducts/17-AAG(Geldan
Combining the two NSCLC patient cohorts, the presence of nontarget mutations at mAF 1% predicts for high sensitivity ( 95%) for identifying the presence of the known driver mutation, whereas mAF of ≤ 1% confers sensitivity of only 26%-54% across platforms. Focusing on 21 false-negative cases where the driver mutation was not detected on plasma next-generation sequencing, other mutations (presumably clonal hematopoiesis) were detected at ≤ 1% AF in 14 (67%). Plasma cfDNA genotyping is highly sensitive when adequate
Like
Comment
Share
